Effectiveness of Trans-Arterial Chemo Embolization for Hepatocellular Carcinoma on Follow-Up CT Triphasic Liver

NCT07048665 | Active Not Recruiting DMC

• 1 other identifier: MSAHSW/Batch-Fall23/906
• Study Type: observational
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

"HCC is a major challenge due to greater recurrence rates and variable treatment responses. TACE is widely used, but its success relies on accurate follow-up imaging. CT Triphasic Liver Imaging plays a vital role in assessing treatment response, guiding clinical decisions, and improving patient outcomes. The purpose of this study is to investigate the relationship between response of treatment, gender, age, and the cause of HCC. The purpose of the study is to evaluate how well TACE (trans-arterial chemoembolization) works for patients with HCC.

Conditions

Hepatocellular Carcinoma

Outcome Measures

Primary Outcomes (1)

• self admisistered questioner

  self-administered questionnaire for the evaluation of HCCT, having a score range from 0 to 50. The more the score shows that issues worsen.

  12 Months

Study Arms (1)

CT Images

Diagnostic Test: CT Imagesa in HCCT

Interventions

CT Imagesa in HCCT DIAGNOSTIC_TEST

Cross-sectional imaging with computed tomography (CT) scanning and magnetic resonance imaging (MRI) is most commonly used to detect hepatocellular carcinoma (HCC). CT scanning is frequently the first examination; however, MRI has superior contrast resolution and may better detect lesions less than 1 cm in diameter

CT Images

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

his will be a retrospective observational study aimed at evaluating the effectiveness of Trans-Arterial Chemo-Embolization in the management of Hepatocellular Carcinoma (HCC) using follow-up CT Triphasic Liver imaging. Patient records and imaging data from past cases will be reviewed to assess post- treatment tumor response and progression.

You may qualify if:

• Both Male and Female.
• Patients diagnosed with HCC who underwent TACE.
• Patients with no portal vein tumor thrombus (PVTT) or no extra Extrahepatic Metastases at the time of initial TACE treatment.
• Patients who underwent TACE within last your years from the study start date.

You may not qualify if:

• Patients with incomplete or missing medical records and imaging studies.
• Patients with a history of severe comorbidities that might interfere with treatment response evaluation
• Patients who were contraindicated for CT scans at the time of follow-up.
• Patients that are contradicted with CT scan.
• Patient who underwent TACE more than four years before the study period.

Sponsors & Collaborators

• Superior University: lead

Study Sites (1)

AYK Hospital

Lahore, Pakistan

Location

MeSH Terms

Conditions

Carcinoma, Hepatocellular

Condition Hierarchy (Ancestors)

Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Liver Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Digestive System Diseases; Liver Diseases

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: June 24, 2025
• First Posted: July 2, 2025
• Study Start: March 17, 2025
• Primary Completion: August 30, 2025
• Study Completion: February 28, 2026
• Last Updated: July 2, 2025

Record last verified: 2025-06

Data Sharing

• IPD Sharing: Will not share

Locations

PA (1)